Lives Of Patients With HER2-Positive Breast Cancer Prolonged By Targeted Therapy

[News]

Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Center. Blackwell presented the findings at the CTRC-AACR San Antonio Breast Cancer Symposium...

More... (http://www.medicalnewstoday.com/articles/173896.php)